Hepatitis B Surface Antigen (Hbsag) Decrease and Serum Interferon-Inducible Protein-10 Levels as Predictive Markers for Hbsag Loss during Treatment with Nucleoside/Nucleotide Analogues
Free accessResearch articleFirst published online August, 2011
Hepatitis B Surface Antigen (Hbsag) Decrease and Serum Interferon-Inducible Protein-10 Levels as Predictive Markers for Hbsag Loss during Treatment with Nucleoside/Nucleotide Analogues
Hepatitis B surface antigen (HBsAg) loss is the ultimate goal of antiviral therapy and its prediction may be important for treatment individualization. Quantitative HBsAg (qHBsAg) has been shown to predict response to interferon-α, but few studies have analysed qHBsAg during treatment with nucleoside/nucleotide analogues (NAs). Serum interferon-inducible protein-10 (IP-10) has been associated with treatment response in hepatitis C, but data in chronic hepatitis B are lacking. Here, we aimed to investigate potential factors predictive for HBsAg loss.
Methods
HBsAg was quantified at multiple time points in 126 patients with chronic HBV infection; 95 received NA treatment for 6–107 months. At an early time point (first 6 months of therapy) and late time point after virological response (VR; HBV DNA<100 IU/ ml), we distinguished three patterns of HBsAg decrease: strong decrease (>0.5 log10), moderate decrease (10% to 0.5 log10) and no decrease (<10%). In addition to conventional biochemical and virological parameters, we analysed serum IP-10 levels in 55 patients.
Results
Early and late HBsAg kinetics did not correlate. Overall, 42% of patients with a strong HBsAg decrease 2 years after VR cleared HBsAg. Importantly, no patient without a late HBsAg decrease >0.5 log10 cleared HBsAg. By contrast, early HBsAg decrease after 6 months of NA therapy was not associated with HBsAg loss. Baseline serum IP-10 levels were associated with late but not early HBsAg kinetics and were highest in patients with HBsAg loss.
Conclusions
Monitoring qHBsAg after successful HBV DNA suppression might be useful to identify patients who clear HBsAg, implicating finite NA treatment. The role of IP-10 as predictive marker for HBsAg loss should be further evaluated.
References
1.
EASL Clinical Practice Guidelines.Management of chronic hepatitis B. J Hepatol2009; 50: 227–242.
2.
GanemD., PrinceA.M.Hepatitis B virus infection – natural history and clinical consequences. N Engl J Med2004; 350: 1118–1129.
3.
LiawY.F., SungJ.J., ChowW.C.Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med2004; 351: 1521–1531.
4.
PapatheodoridisG.V., LamperticoP., ManolakopoulosS., LokA.Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol2010; 53: 348–356.
5.
ReijndersJ.G., PerquinM.J., ZhangN., HansenB.E., JanssenH.L.Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology2010; 139: 491–498.
6.
CornbergM., ProtzerU., DollingerM.M.Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol2007; 45: 1281–1328.
7.
GishR.G., ChangT.T., LaiC.L.Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat2010; 17: 16–22.
8.
MarcellinP., ChangT.T., LimS.G.Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology2008; 48: 750–758.
9.
WursthornK., JungM., RivaA.Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology2010; 52: 1611–1620.
10.
WursthornK., JaroszewiczJ., ZacherB.J.Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol2011; 50: 292–296.
11.
JaroszewiczJ., Calle SerranoB., WursthornK.Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol2010; 52: 514–522.
12.
NguyenT., ThompsonA.J., BowdenS.Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol2010; 52: 508–513.
13.
ChanH.L., WongV.W., WongG.L., TseC.H., ChanH.Y., SungJ.J.A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology2010; 52: 1232–1241.
14.
ThompsonA.J., NguyenT., IserD.Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology2010; 51: 1933–1944.
15.
BrunettoM.R., OliveriF., ColombattoP.Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology2010; 139: 483–490.
16.
BrunettoM.R., MoriconiF., BoninoF.Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology2009; 49: 1141–1150.
17.
MoucariR., MackiewiczV., LadaO.Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology2009; 49: 1151–1157.
18.
SonneveldM.J., RijckborstV., BoucherC.A., HansenB.E., JanssenH.L.Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology2010; 52: 1251–1257.
19.
RijckborstV., HansenB.E., CakalogluY.Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology2010; 52: 454–461.
20.
WiegandJ., WedemeyerH., FingerA.A decline in hepatitis B virus surface antigen (HBsAg) predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels. Antivir Ther2008; 13: 547–554.
21.
BorgnietO., ParvazP., BouixC.Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. J Med Virol2009; 81: 1336–1342.
22.
ManesisE.K., HadziyannisE.S., AngelopoulouO.P., HadziyannisS.J.Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther2007; 12: 73–82.
23.
HeathcoteE.J., MarcellinP., ButiM.Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology2011; 140: 132–143.
24.
ReibergerT., AberleJ.H., KundiM.IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV–HCV coinfection. Antivir Ther2008; 13: 969–976.
25.
DarlingJ.M., AerssensJ., FanningG.Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology2011; 53: 14–22.
26.
KakimiK., LaneT.E., WielandS.Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med2001; 194: 1755–1766.
27.
WielandS., ThimmeR., PurcellR.H., ChisariF.V.Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A2004; 101: 6669–6674.
28.
CornbergM., JaroszewiczJ., MannsM.P., WedemeyerH.Treatment of chronic hepatitis B. Minerva Gastroenterol Dietol2010; 56: 451–465.
29.
ChangT.T., LaiC.L., Kew YoonS.Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology2010; 51: 422–430.
30.
DengG., ZhouG., ZhangR.Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology2008; 134: 716–726.
31.
Sarasin-FilipowiczM., OakeleyE.J., DuongF.H.Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A2008; 105: 7034–7039.
32.
LütgehetmannM., BornscheuerT., VolzT.Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology2011; 140: 2074–2083.
33.
MuellerS.N., AhmedR.High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A2009; 106: 8623–8628.
34.
Op den BrouwM.L., BindaR.S., van RoosmalenM.H.Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology2009; 126: 280–289.
35.
ReignatS., WebsterG.J., BrownD.Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med2002; 195: 1089–1101.
36.
WuZ.G., YanW.M., GuoW.Telbivudine preserves T-helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis. J Viral Hepat2010; 17Suppl 1: 24–33.
37.
BoniC., BertolettiA., PennaA.Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest1998; 102: 968–975.
38.
BoniC., PennaA., BertolettiA.Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol2003; 39: 595–605.
